ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

ClinicalTrials.gov ID: NCT05549505

Public ClinicalTrials.gov record NCT05549505. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 21, 2026, 1:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Randomized, Non-comparative Phase 2 Study of ARV-471 or Anastrozole in Post-menopausal Women With ER+/HER2- Breast Cancer in the Neoadjuvant Setting

Study identification

NCT ID
NCT05549505
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Arvinas Inc.
Industry
Enrollment
152 participants

Conditions and interventions

Conditions

Interventions

  • ARV-471 Drug
  • Anastrozole Drug
  • Surgical resection of breast tumor Procedure

Drug · Procedure

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 14, 2023
Primary completion
Jul 12, 2024
Completion
Jul 24, 2024
Last update posted
Aug 28, 2025

2023 – 2024

United States locations

U.S. sites
13
U.S. states
8
U.S. cities
13
Facility City State ZIP Site status
Clinical Trial Site Springdale Arkansas 72762
Clinical Trial Site Los Angeles California 90095
Clinical Trial Site Torrance California 90505
Clinical Trial Site Van Nuys California 91405
Clinical Trial Site Fort Lauderdale Florida 33308
Clinical Trial Site Fort Myers Florida 33901
Clinical Trial Site Orlando Florida 32806
Clinical Trial Site West Palm Beach Florida 33401
Clinical Trial Site Iowa City Iowa 52242
Clinical Trial Site Springfield Massachusetts 01199
Clinical Trial Site St Louis Missouri 63110
Clinical Trial Site Nashville Tennessee 37203
Clinical Trial Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05549505, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 28, 2025 · Synced May 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05549505 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →